S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive [Yahoo! Finance]
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.
Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years [Yahoo! Finance]
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.